Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hallucinogens | 12 | 2019 | 71 | 3.250 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 12 | 2020 | 68 | 2.370 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 2019 | 5 | 1.090 |
Why?
|
| Speech | 2 | 2020 | 84 | 0.680 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 75 | 0.670 |
Why?
|
| Internet | 3 | 2013 | 312 | 0.670 |
Why?
|
| Emotions | 3 | 2016 | 341 | 0.640 |
Why?
|
| Central Nervous System Stimulants | 3 | 2016 | 216 | 0.560 |
Why?
|
| Double-Blind Method | 12 | 2020 | 1823 | 0.550 |
Why?
|
| Salvia | 2 | 2010 | 2 | 0.490 |
Why?
|
| Methamphetamine | 6 | 2011 | 82 | 0.460 |
Why?
|
| Theobromine | 1 | 2013 | 3 | 0.460 |
Why?
|
| Affect | 3 | 2013 | 386 | 0.460 |
Why?
|
| Caffeine | 1 | 2013 | 81 | 0.420 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2010 | 4 | 0.390 |
Why?
|
| Hallucinations | 1 | 2010 | 27 | 0.390 |
Why?
|
| Vision, Ocular | 1 | 2010 | 71 | 0.380 |
Why?
|
| Vision Disorders | 1 | 2010 | 75 | 0.370 |
Why?
|
| Data Collection | 2 | 2013 | 372 | 0.370 |
Why?
|
| Self Report | 2 | 2010 | 288 | 0.360 |
Why?
|
| Young Adult | 12 | 2020 | 5974 | 0.350 |
Why?
|
| Plant Extracts | 2 | 2010 | 244 | 0.340 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2008 | 3 | 0.340 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2008 | 15 | 0.340 |
Why?
|
| Endocannabinoids | 1 | 2008 | 27 | 0.330 |
Why?
|
| Cross-Over Studies | 5 | 2019 | 399 | 0.320 |
Why?
|
| Adult | 20 | 2020 | 25640 | 0.300 |
Why?
|
| Surveys and Questionnaires | 4 | 2010 | 2501 | 0.290 |
Why?
|
| Healthy Volunteers | 3 | 2016 | 143 | 0.280 |
Why?
|
| Substance-Related Disorders | 3 | 2013 | 394 | 0.280 |
Why?
|
| Male | 22 | 2020 | 40956 | 0.250 |
Why?
|
| Social Behavior | 3 | 2016 | 294 | 0.250 |
Why?
|
| Interpersonal Relations | 2 | 2016 | 170 | 0.240 |
Why?
|
| Heart Rate | 5 | 2014 | 492 | 0.240 |
Why?
|
| Empathy | 2 | 2016 | 147 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2013 | 1961 | 0.220 |
Why?
|
| Female | 20 | 2020 | 44507 | 0.210 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2010 | 27 | 0.210 |
Why?
|
| Humans | 29 | 2020 | 86601 | 0.210 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2010 | 15 | 0.200 |
Why?
|
| Dextromethorphan | 1 | 2000 | 11 | 0.200 |
Why?
|
| Area Under Curve | 2 | 2019 | 334 | 0.190 |
Why?
|
| Naloxone | 2 | 1999 | 59 | 0.180 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1999 | 4 | 0.180 |
Why?
|
| Buprenorphine | 2 | 1999 | 33 | 0.180 |
Why?
|
| Narcotic Antagonists | 2 | 1999 | 154 | 0.160 |
Why?
|
| Cognition | 2 | 2015 | 570 | 0.160 |
Why?
|
| Language | 1 | 2020 | 151 | 0.160 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 502 | 0.160 |
Why?
|
| Opioid-Related Disorders | 2 | 1999 | 161 | 0.150 |
Why?
|
| Adolescent | 4 | 2013 | 8979 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2013 | 684 | 0.130 |
Why?
|
| Disclosure | 1 | 2016 | 108 | 0.130 |
Why?
|
| Blood Pressure | 4 | 2014 | 1143 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 86 | 0.120 |
Why?
|
| Anesthetics, Dissociative | 1 | 2013 | 5 | 0.120 |
Why?
|
| Ketamine | 1 | 2013 | 24 | 0.110 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 188 | 0.110 |
Why?
|
| Urologic Diseases | 1 | 2013 | 45 | 0.110 |
Why?
|
| Substance Abuse Detection | 1 | 2011 | 12 | 0.100 |
Why?
|
| Diterpenes, Clerodane | 1 | 2010 | 1 | 0.100 |
Why?
|
| Urinalysis | 1 | 2011 | 33 | 0.100 |
Why?
|
| Amines | 1 | 2010 | 27 | 0.100 |
Why?
|
| Nootropic Agents | 1 | 2010 | 10 | 0.100 |
Why?
|
| Ethics, Clinical | 1 | 2010 | 48 | 0.090 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2010 | 22 | 0.090 |
Why?
|
| Placebos | 1 | 2010 | 218 | 0.090 |
Why?
|
| Weight Gain | 1 | 2011 | 123 | 0.090 |
Why?
|
| Central Nervous System Depressants | 1 | 2010 | 45 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 123 | 0.090 |
Why?
|
| Impulsive Behavior | 1 | 2013 | 281 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 2008 | 121 | 0.090 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 107 | 0.090 |
Why?
|
| Attention | 1 | 2013 | 388 | 0.090 |
Why?
|
| Nasal Decongestants | 1 | 2008 | 10 | 0.090 |
Why?
|
| Bicycling | 1 | 2008 | 12 | 0.080 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 15 | 0.080 |
Why?
|
| Nerve Fibers | 1 | 2008 | 46 | 0.080 |
Why?
|
| Athletic Performance | 1 | 2008 | 31 | 0.080 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 130 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 106 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2008 | 152 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2008 | 115 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2008 | 347 | 0.080 |
Why?
|
| Visual Perception | 1 | 2010 | 319 | 0.080 |
Why?
|
| Middle Aged | 6 | 2010 | 25017 | 0.080 |
Why?
|
| Cerebellum | 1 | 2008 | 247 | 0.070 |
Why?
|
| Research Design | 2 | 2013 | 594 | 0.060 |
Why?
|
| Aged | 2 | 2010 | 18402 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2002 | 36 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2010 | 4210 | 0.050 |
Why?
|
| Animals | 4 | 2008 | 26581 | 0.050 |
Why?
|
| Papio | 1 | 2001 | 82 | 0.050 |
Why?
|
| Time Factors | 4 | 2010 | 5209 | 0.050 |
Why?
|
| Psycholinguistics | 1 | 2020 | 10 | 0.050 |
Why?
|
| Semantics | 1 | 2020 | 50 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 136 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 678 | 0.040 |
Why?
|
| Oxytocin | 1 | 2020 | 71 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2001 | 199 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 3241 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 894 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2705 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2000 | 710 | 0.040 |
Why?
|
| Rats | 2 | 2001 | 3990 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 1169 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 1718 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2001 | 2261 | 0.030 |
Why?
|
| Dysuria | 1 | 2013 | 8 | 0.030 |
Why?
|
| Hematuria | 1 | 2013 | 49 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2013 | 148 | 0.030 |
Why?
|
| Reaction Time | 1 | 1993 | 309 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2013 | 160 | 0.030 |
Why?
|
| Appetite | 1 | 2011 | 26 | 0.030 |
Why?
|
| Risk Factors | 1 | 2002 | 5416 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 297 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 2010 | 5 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 19 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 92 | 0.020 |
Why?
|
| Deuterium | 1 | 2010 | 33 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 116 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 96 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2010 | 51 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 567 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1993 | 492 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 244 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 124 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2002 | 912 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 129 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 216 | 0.020 |
Why?
|
| Terpenes | 1 | 2008 | 17 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 224 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 319 | 0.020 |
Why?
|
| United States | 1 | 2000 | 6665 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 434 | 0.020 |
Why?
|
| Mice | 1 | 2001 | 11352 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 864 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1849 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 726 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 3674 | 0.010 |
Why?
|
| Prolactin | 1 | 2002 | 88 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 2002 | 51 | 0.010 |
Why?
|
| Hormones | 1 | 2002 | 140 | 0.010 |
Why?
|
| Psychometrics | 1 | 2002 | 327 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 298 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2000 | 156 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 239 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 187 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 48 | 0.010 |
Why?
|
| Narcotics | 1 | 1999 | 69 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2000 | 456 | 0.010 |
Why?
|
| Morphine | 1 | 1999 | 130 | 0.010 |
Why?
|
| Serotonin | 1 | 1993 | 218 | 0.010 |
Why?
|
| Dopamine | 1 | 1993 | 275 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 1219 | 0.010 |
Why?
|